All In Biotech

Drug Trial Radar · NCT02063360

DDI Study of BMS-663068 With Etravirine (ETR) and/or Darunavir (DVR) + Ritonavir (RTV)

Open-Label, Single-Sequence Study to Evaluate the Pharmacokinetic Interaction of BMS-663068 With Darunavir/Ritonavir and/or Etravirine in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Aug 8, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

42

Actual

Start

Feb 1, 2014

Primary completion

May 1, 2014

Study completion May 13, 2014

Sponsor

Lead sponsor
ViiV HealthcareGSK (GSK)
Sponsor type
Industry
Collaborators
GlaxoSmithKline
First posted
Feb 14, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Other
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine if there is an interaction in healthy subjects taking BMS-663068 with Darunavir/Ritonavir and/or Etravirine.

Conditions

  • Infection, Human Immunodeficiency Virus

Interventions

  • BMS-663068Drug

    BMS-663068

  • Darunavir (DRV)Drug

    Darunavir (DRV)

  • Ritonavir (RTV)Drug

    Ritonavir (RTV)

  • Etravirine (ETR)Drug

    Etravirine (ETR)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum observed plasma concentration (Cmax) of BMS-626529Time frame: 20 timepoints up to day 26
  2. Area under the concentration-time curve in 1 dosing interval (AUC(TAU)) of BMS-626529Time frame: 20 timepoints up to day 26

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.